J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount
Executive Summary
Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call
You may also be interested in...
J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes
Johnson & Johnson is taking steps to competitively position Procrit ahead of the changes to Medicare Part B reimbursement in 2005, Biopharmaceuticals Group Chairman Joe Scodari told investors July 13
J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes
Johnson & Johnson is taking steps to competitively position Procrit ahead of the changes to Medicare Part B reimbursement in 2005, Biopharmaceuticals Group Chairman Joe Scodari told investors July 13
EPO Ceasefire? Amgen Aranesp Price To Remain Stable Unless J&J Acts First
Amgen does not intend to continue implementing Aranesp price discounts unless J&J moves first, Amgen Exec VP-Global Commercial Operations George Morrow said during an earnings call April 22